These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9931308

  • 21. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
    Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, Kaisho T, Terada N, Kitamura Y, Kanakura Y.
    Blood; 1999 Feb 15; 93(4):1319-29. PubMed ID: 9949175
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
    Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA.
    Blood; 2002 Jul 15; 100(2):585-93. PubMed ID: 12091352
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Catalytic assessment of the glycine-rich loop of the v-Fps oncoprotein using site-directed mutagenesis.
    Hirai TJ, Tsigelny I, Adams JA.
    Biochemistry; 2000 Oct 31; 39(43):13276-84. PubMed ID: 11052681
    [Abstract] [Full Text] [Related]

  • 25. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
    Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R.
    Mol Cell Biol; 2003 May 31; 23(9):3067-78. PubMed ID: 12697809
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel mutations of KIT gene in two Korean patients: variegated shades of phenotypes in tyrosine kinase 1 domain.
    Lee H, Oh SH, Koo KY, Suzuki T, Lee JS.
    J Dermatol Sci; 2014 Oct 31; 76(1):74-6. PubMed ID: 25176472
    [No Abstract] [Full Text] [Related]

  • 29. In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases.
    Curcio-Morelli C, Gereben B, Zavacki AM, Kim BW, Huang S, Harney JW, Larsen PR, Bianco AC.
    Endocrinology; 2003 Mar 31; 144(3):937-46. PubMed ID: 12586771
    [Abstract] [Full Text] [Related]

  • 30. Thermal stabilization of the catalytic domain of botulinum neurotoxin E by phosphorylation of a single tyrosine residue.
    Blanes-Mira C, Ibañez C, Fernández-Ballester G, Planells-Cases R, Pérez-Payá E, Ferrer-Montiel A.
    Biochemistry; 2001 Feb 20; 40(7):2234-42. PubMed ID: 11329292
    [Abstract] [Full Text] [Related]

  • 31. Transforming mutations in protein-tyrosine kinase genes.
    Cooper JA.
    Bioessays; 1986 Jan 20; 4(1):9-15. PubMed ID: 3539110
    [No Abstract] [Full Text] [Related]

  • 32. Intracellular expression and purification of the c-kit receptor kinase domain in Pichia pastoris.
    Lam LP, Berger SA.
    Biotechniques; 1997 Jul 20; 23(1):82, 83-6. PubMed ID: 9232234
    [No Abstract] [Full Text] [Related]

  • 33. Expression of Active Staphylococcus aureus Tyrosine Kinases in a Human Cell Line.
    Fukazawa H, Fukuyama M, Miyazaki Y.
    Biol Pharm Bull; 2019 Jul 20; 42(3):411-416. PubMed ID: 30828073
    [Abstract] [Full Text] [Related]

  • 34. Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity.
    Telerman A, Amson R, Zakut-Houri R, Givol D.
    Mol Cell Biol; 1988 Apr 20; 8(4):1498-503. PubMed ID: 2837645
    [Abstract] [Full Text] [Related]

  • 35. Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.
    Klug LR, Corless CL, Heinrich MC.
    J Clin Oncol; 2021 May 20; 39(15):1674-1686. PubMed ID: 33797935
    [No Abstract] [Full Text] [Related]

  • 36. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures.
    Diwanji D, Thaker T, Jura N.
    IUBMB Life; 2019 Jun 20; 71(6):706-720. PubMed ID: 31046201
    [Abstract] [Full Text] [Related]

  • 37. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
    Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F.
    Drug Des Devel Ther; 2016 Jun 20; 10():2443-59. PubMed ID: 27536065
    [Abstract] [Full Text] [Related]

  • 38. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
    Cruse G, Metcalfe DD, Olivera A.
    Immunol Allergy Clin North Am; 2014 May 20; 34(2):219-37. PubMed ID: 24745671
    [Abstract] [Full Text] [Related]

  • 39. Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.
    Verstraete K, Savvides SN.
    Nat Rev Cancer; 2012 Nov 20; 12(11):753-66. PubMed ID: 23076159
    [Abstract] [Full Text] [Related]

  • 40. Recombinant protein expression in Pichia pastoris.
    Cregg JM, Cereghino JL, Shi J, Higgins DR.
    Mol Biotechnol; 2000 Sep 20; 16(1):23-52. PubMed ID: 11098467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.